Related Experiment Video
Updated: Feb 20, 2026

Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane
Published on: December 9, 2022
New data on chronic venous disease: a new place for Cyclo 3® Fort
Stavros K Kakkos1, Eliete Bouskela2, Arkadiusz Jawien3
1Department of Vascular Surgery, University Hospital of Patras, Patras, Greece - kakkos@upatras.gr.
Insights
The Ruscus, hesperidin methyl chalcone (HMC), and vitamin C combination (Cyclo 3® Fort) effectively treats chronic venous disease (CVD) symptoms. New guidelines should recommend this combination with a Grade 1A rating.
Area of Science:
- Vascular Medicine
- Pharmacology
- Evidence-Based Medicine
Background:
- Chronic venous disease (CVD) knowledge is advancing, necessitating updated management guidelines.
- New data on therapies for CVD requires reevaluation of current recommendations.
Purpose of the Study:
- To update recommendations for chronic venous disease (CVD) management.
- To evaluate the efficacy of the Ruscus, hesperidin methyl chalcone (HMC), and vitamin C combination (Cyclo 3® Fort).
Main Methods:
- A symposium reviewed recent developments on Cyclo 3® Fort.
- In-vivo pharmacological experiments and a meta-analysis were presented.
- Information on prospective 2018 CVD guidelines was shared.
Main Results:
- The combination of Ruscus, HMC, and vitamin C demonstrated significant effects on pain, heaviness, swelling, tingling, ankle circumference, and global symptoms.
- Evidence analysis supported a Grade A efficacy for the treatment.
Conclusions:
- The Ruscus, HMC, and vitamin C combination (Cyclo 3® Fort) is highly effective for managing CVD symptoms.
- A Grade 1A recommendation for this combination in future CVD guidelines is warranted.
Abstract:
With our increasing knowledge of the epidemiology, pathophysiology, investigation and clinical aspects of chronic venous disease (CVD) and new data on the various therapies available, an update of the recommendations on CVD and its management appears to be necessary. The symposium New Data on Chronic Venous Disease: A New Place for Cyclo 3® Fort, held during the annual meeting of the European Venous Forum on June 30th, 2017 in Porto, Portugal, reported the recent developments on the Ruscus, hesperidin methyl chalcone (HMC), and vitamin C combination (Cyclo 3® Fort), including the results of a series of in-vivo pharmacological experiments and a recent meta-analysis. Additionally, the symposium provided first-hand information on the process, rules, main findings, and expected contents of the prospective 2018 CVD guidelines. Analysis of the evidence showed that the effect of the Ruscus, HMC, and vitamin C combination on pain, heaviness, feeling of swelling, tingling, ankle circumference and global symptoms score reached Grade A. Therefore, the new guidelines should specify that the Ruscus, HMC, and vitamin C combination merits a Grade 1A recommendation.
Related Concept Videos
Varicose Veins II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Varicose Veins I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis I: Introduction
Venous Thrombosis IV: Nursing Management

